Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Receives Notice of Allowance on Patent Application Covering Delivery Tech

Premium

Arrowhead Research this week announced that it has received a notice of allowance from the US Patent and Trademark Office that it will be granted a patent on an application covering its dynamic polyconjugate delivery technology.

The patent application, No. 20120165393, is entitled “Peptide-based In Vivo siRNA Delivery System” and claims the targeted delivery of RNAi oligos to hepatocytes when administered along with co-targeted melittin delivery peptides.

The peptides, the patent application indicates, enable cellular membrane penetration.

The patent application, Arrowhead noted, specifically covers the delivery technology being used with the company’s preclinical hepatitis B therapy ARC-520, which is slated to enter phase I testing this year (GSN 2/14/2013).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.